Igenica
Biopharmaceutical company developing antibody-based therapeutics for the treatment of cancer.
Launch date
Employees
Market cap
-
Enterprise valuation
€4—7m (Dealroom.co estimates Jun 2015.)
Burlingame California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$3.1m | Series A | ||
$24.0m | Series B | ||
$33.0m | Series C | ||
N/A | $14.0m | Series C | |
$216k | Grant | ||
N/A | $5.1m | Early VC | |
N/A | $1.2m | Early VC | |
Total Funding | €73.3m |
Recent News about Igenica
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.